Anti-aggravating effects of kakkonto, a Chinese herb, for common colds: a randomized controlled trial

Research Project

Project/Area Number	22590650
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Single-year Grants
Section	一般
Research Field	General internal medicine (including Psychosomatic medicine)
Research Institution	Kyoto University
Principal Investigator	GOTO Masashi 京都大学, 保健管理センター, 准教授 (60402955)
Co-Investigator(Kenkyū-buntansha)	KAWAMURA Takashi 京都大学, 保健管理センター, 教授 (10252230)
Project Period (FY)	2010 – 2012
Project Status	Completed (Fiscal Year 2012)
Budget Amount *help	¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000) Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000) Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Keywords	東洋医学 / 感冒 / 葛根湯 / ランダム化比較試験
Research Abstract	This study aimed to examine whether Kakkonto prevents aggravation of cold symptoms if taken at an early stage of illness comparing with a well-selected western-style multiple cold medicine, Pabron Gold. A total of 340 participants (168 in the Kakkonto group and 172 in the Pabron grou p) were included in the analyses. The proportion of the participants whose colds were aggravated was 22.6% in the Kakkonto group and 25.0% in the Pabron group (P=0.66).